Anti diabetic effect of Bergenia ligulata (Pakhanbed )

Effect of Pakhanbed (Bergenia ligulata Wall.) as adjuvant in the management of Diabetes mellitus Type-2: A randomized controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019087

Enrollment

Registered

2019-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: A Single Unani Drug,Pakhanbed (Bergenia ligulata Wall.): Pakhanbed (Bergenia ligulata Wall.) Given orally in the form of capsules 4mg / day in 2 divided doses , 2 capsules in mrg and t

Eligibility

Inclusion criteria

Inclusion criteria: 1.Fasting blood sugar (FBS) =126 mg/dl-= 200mg/dl 2.Post Prandial blood sugar(PPBS)= 200 mg/dl-=300 mg /dl 3.HbA1c > 6.5 - =10% 4.Patients taking

Exclusion criteria

Exclusion criteria: 1.Fasting blood sugar (FBS) > 200mg/dl 2.Post Prandial blood sugar (PPBS) > 300mg/dl 3.Known cases of Type 2 Diabetes Mellitus with complications. 4.Pregnant & lactating Women. 5.History of any systemic illnesses 6.History of any other disorders of metabolism. 7.Patients who are on medication > 3 hypoglycemic drugs

Design outcomes

Primary

Measure	Time frame
Reduction in FBS and PPBSTimepoint: Reduction in FBS and PPBS at 4 and 8 weeks	—

Secondary

Measure	Time frame
1. Improvement in Asian DQOL 2. Reduction in HbA1c Timepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Muzafar Din Ahmad Bhat

National institute of Unani medicine

drmuzaffar79@gmail.com9590366192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026